Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Citation data:

Journal of bone oncology, ISSN: 2212-1366, Vol: 7, Page: 1-12

Publication Year:
2017
Usage 85
Abstract Views 82
Link-outs 3
Mentions 5
News Mentions 5
Social Media 64
Shares, Likes & Comments 39
Tweets 25
Citations 7
Citation Indexes 7
PMID:
28413771
DOI:
10.1016/j.jbo.2017.03.001
Author(s):
Hadji, Peyman; Aapro, Matti S; Body, Jean-Jacques; Gnant, Michael; Brandi, Maria Luisa; Reginster, Jean Yves; Zillikens, M Carola; Glüer, Claus-C; de Villiers, Tobie; Baber, Rod; Roodman, G David; Cooper, Cyrus; Langdahl, Bente; Palacios, Santiago; Kanis, John; Al-Daghri, Nasser; Nogues, Xavier; Eriksen, Erik Fink; Kurth, Andreas; Rizzoli, Rene; Coleman, Robert E Show More Hide
Publisher(s):
Elsevier BV
Tags:
Medicine
Most Recent Tweet View All Tweets
Most Recent News Mention
review description
Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL).